InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
1
T+90 胜率
100%
T+90 平均收益
+92.0%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the detailed record of transactions filed by Kreher Nerissa, Directrice Médicale. Officer active across 2 companies, notably Entrada Therapeutics, Inc.. Cumulatively, 17 filings have been logged. Breakdown: 1 buy · 1 sell. Total volume traded: €74k. History available since 29 December 2021. The latest transaction was disclosed on 19 November 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Kreher Nerissa
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
21,000 股0Common SharesSEC:0000912282-25-001290:0
3,076 股@ US$3.25100.0% 占其流量Common SharesSEC:0000912282-25-000699:0
标准退出：2025年9月11日 (T+90)
9,000 股0Common SharesSEC:0000912282-25-000668:0
25,500 股0Common SharesSEC:0000912282-25-000178:0
14,200 股0Common StockSEC:0001689375-23-000062:0
10,348 股@ US$2.1014.4% 占其流量Common StockSEC:0001689375-23-000050:0
14,200 股0Common StockSEC:0001689375-23-000027:0
28,400 股0Common StockSEC:0001689375-23-000011:0
5,200 股@ US$13.448447.4% 占其流量Common StockSEC:0001689375-23-000001:0
8,040 股@ US$2.1012.3% 占其流量Common StockSEC:0001689375-22-000039:0
3,068 股@ US$2.104.8% 占其流量Common StockSEC:0001689375-22-000033:0
3,341 股@ US$2.105.2% 占其流量Common StockSEC:0001689375-22-000030:0
106 股@ US$2.100.2% 占其流量Common StockSEC:0001689375-22-000026:0
1,221 股@ US$2.101.9% 占其流量Common StockSEC:0001689375-22-000020:0
5,172 股0Common StockSEC:0001104659-22-097874:0
10,344 股0Common StockSEC:0001104659-22-030005:0
5,200 股@ US$2.107.5% 占其流量Common StockSEC:0001104659-21-154295:0
17 条申报中的 17 条
About Kreher Nerissa
KREHER NERISSA is Directrice Médicale. She has 17 filings in total, and among the sampled recent filings, purchases amount to EUR 8618 and sales to EUR 65597, over the period from 2021-12-29 to 2025-11-21. She is linked to Entrada Therapeutics, Inc. as Chief Medical Officer and to Rezolute, Inc. as Director.
